Back to search results

Mindful Self-Compassion for Anxiety and Depression

This study is testing an 8-week Mindful Self-Compassion training program to see if it can help reduce symptoms of anxiety and depression. It's for adults aged 18 to 75 who have been diagnosed with an anxiety disorder (like generalized anxiety disorder, social anxiety disorder, or panic disorder) or major depressive disorder, and who also score low on self-compassion. The study will compare people who receive the Mindful Self-Compassion training to a group that does not. We will measure changes in anxiety and depression symptoms using the Hospital Anxiety and Depression Scale after 8 weeks to see if the training is successful. The current status of this study is unclear.

Study design
This interventional study plans to enroll 40 participants. It compares an 8-week Mindful Self-Compassion training to a control group that does not receive the intervention.
What's involved
You would participate in all testing visits and the assigned treatment. The Mindful Self-Compassion training lasts for 8 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at 8 weeks, which is when the intervention concludes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05671419

Mindful Self-Compassion for Anxiety Disorders and Depression

Recruiting
NAAges 18–75InterventionalTreatment
Georgetown University
~40 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Mindful Self-Compassion

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hospital Anxiety and Depression Scale
Measured over 8 weeks

Conditions

Anxiety Disorders
Generalized Anxiety Disorder
Social Anxiety Disorder
Social Phobia
Panic Disorder
Agoraphobia
Major Depressive Disorder

Explore related trials

AgoraphobiaGeneralized Anxiety DisorderPanic DisorderSocial Anxiety DisorderUnipolar Depression

NCT05671419

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Georgetown University Medical Center

    Washington D.C., District of Columbiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Elizabeth Hoge, MD · PRINCIPAL_INVESTIGATOR · Georgetown University

Who to contact

Charisma, Study Coordinator
[email protected]
202-687-7283
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must have a primary anxiety disorder (social anxiety disorder, generalized anxiety disorder, panic disorder, or agoraphobia) or major depressive disorder, current
Must score low on self-compassion, as measured by the self-compassion scale
Must understand study procedure and willing to participate in all testing visits, and treatment as assigned
must be able to give informed consent to the study procedures

Exclusion

Comorbid psychiatric disorder other than anxiety or depression, such as psychotic disorder, obsessive compulsive disorder, eating disorders (i.e., anorexia and bulimia), bipolar disorder; developmental or organic mental disorders; and current (past 6 months) substance use disorders and current post-traumatic stress disorder as assessed by clinician at screening visit
A serious medical condition that may result in surgery or hospitalization.
A history of head trauma causing prolonged loss of consciousness, or ongoing cognitive impairment
Inability to understand study procedures or informed consent process, or significant personality dysfunction likely to interfere with study participation (assessed during the clinical interview).
Subjects who will be non-compliant with the study procedures. This may include planned travel out of town.
Subjects taking some psychiatric medication such as barbiturates or antipsychotics. Sleep medications and some anti-depressants will be allowed, if the subject has been taken at stable dose 8 weeks prior to baseline and the patient plans to continue at the same dose through the trial.
Concurrent psychotherapy initiated within 1 month of screen interview, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety (such as Cognitive Behavioral Therapy).
Individuals who have completed a course of MSC or an equivalent meditation training in the last year.
Individuals reporting significant active suicidal ideation or suicidal behaviors within the past year.
Individuals with a medical condition (i.e., epilepsy) that may be exacerbated by study treatment, as determined by a study physician or nurse practitioner based on history, physical, and/or labs.
Adults unable to consent
Pregnant women
Prisoners

What this trial measures

  • Hospital Anxiety and Depression Scale8 weeks

    Self-report questionnaire of anxiety and depression symptoms, 14 items using 4-point likert scale